These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 3758141)

  • 41. Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic.
    Goland S; Naugolny V; Korbut Z; Rozen I; Caspi A; Malnick S
    Eur J Intern Med; 2011 Aug; 22(4):424-7. PubMed ID: 21767763
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure.
    Cavallari LH; Fashingbauer LA; Beitelshees AL; Groo VL; Southworth MR; Viana MA; Williams RE; Dunlap SH
    Pharmacotherapy; 2004 Jun; 24(6):750-6. PubMed ID: 15222665
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug attributed alterations in potassium handling in congestive cardiac failure.
    Lawson DH; O'Connor PC; Jick H
    Eur J Clin Pharmacol; 1982; 23(1):21-5. PubMed ID: 7128669
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metolazone and spironolactone in cirrhosis and the nephrotic syndrome.
    Lang GR; Westenfelder C; Nascimento L; Dhupelia VB; Arruda JA; Kane RE
    Clin Pharmacol Ther; 1977 Feb; 21(2):234-43. PubMed ID: 319937
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
    Muzzarelli S; Maeder MT; Toggweiler S; Rickli H; Nietlispach F; Julius B; Burkard T; Pfisterer ME; Brunner-La Rocca HP;
    Am J Cardiol; 2012 Mar; 109(5):693-8. PubMed ID: 22152974
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral magnesium supplementation restores the concentrations of magnesium, potassium and sodium-potassium pumps in skeletal muscle of patients receiving diuretic treatment.
    Dørup I; Skajaa K; Thybo NK
    J Intern Med; 1993 Feb; 233(2):117-23. PubMed ID: 8381850
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Usefulness of spironolactone in a specialized heart failure clinic.
    Sligl W; McAlister FA; Ezekowitz J; Armstrong PW
    Am J Cardiol; 2004 Aug; 94(4):443-7. PubMed ID: 15325926
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Increased breast cancer risk caused by spironolactone?].
    Fanta S
    Dtsch Med Wochenschr; 2012 Sep; 137(38):1840. PubMed ID: 23133848
    [No Abstract]   [Full Text] [Related]  

  • 49. Efficacy of spironolactone therapy in patients with true resistant hypertension.
    de Souza F; Muxfeldt E; Fiszman R; Salles G
    Hypertension; 2010 Jan; 55(1):147-52. PubMed ID: 19858405
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure.
    Ferreira JP; Santos M; Almeida S; Marques I; Bettencourt P; Carvalho H
    Eur J Intern Med; 2014 Jan; 25(1):67-72. PubMed ID: 24070521
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fixed-dose combination diuretics in congestive heart failure: an evaluation.
    Levy B
    J Clin Pharmacol; 1979; 19(11-12):743-6. PubMed ID: 395175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men.
    Siegel D; Hulley SB; Black DM; Cheitlin MD; Sebastian A; Seeley DG; Hearst N; Fine R
    JAMA; 1992 Feb; 267(8):1083-9. PubMed ID: 1735925
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Spironolactone in severe heart failure: enhances efficacy of diuretic + ACE inhibitor combinations.
    Prescrire Int; 2000 Oct; 9(49):158-9. PubMed ID: 11603418
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potassium-sparing agents during diuretic therapy in hypertension.
    McKenna TJ; Donohoe JF; Brien TG; Healy JJ; Canning BS; Muldowney FP
    Br Med J; 1971 Jun; 2(5764):739-41. PubMed ID: 5090761
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
    Pitt B; Zannad F; Remme WJ; Cody R; Castaigne A; Perez A; Palensky J; Wittes J
    N Engl J Med; 1999 Sep; 341(10):709-17. PubMed ID: 10471456
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of aldosterone in the antihypertensive effect of spironolactone in essential hypertension.
    Benraad H; Drayer J; Hoefnagels W; Kloppenborg P; Benraad T
    Clin Pharmacol Ther; 1978 Dec; 24(6):638-43. PubMed ID: 710023
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Captopril and spironolactone therapy for refractory congestive heart failure.
    Dahlström U; Karlsson E
    Am J Cardiol; 1993 Jan; 71(3):29A-33A. PubMed ID: 8422001
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of spironolactone (Aldactone) and methyldopa in low and normal renin hypertension.
    Solheim SB; Sundsfjord JA; Giezendanner L
    Acta Med Scand; 1975 Jun; 197(6):451-6. PubMed ID: 1098396
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changes in urinary electrolytes versus serum electrolytes during treatment of primary hypertension with chlorthalidone alone and in combination with spironolactone.
    Falch DK; Schreiner AM
    Acta Med Scand; 1981; 209(1-2):111-4. PubMed ID: 7010926
    [No Abstract]   [Full Text] [Related]  

  • 60. Plasma and muscle electrolytes in patients receiving diuretics. Methodological and clinical considerations.
    Bergström J
    Acta Cardiol; 1973; ():Suppl 17:15-24. PubMed ID: 4543685
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.